Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

(2017) R. Kefford et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

(2017) J. R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

(2011) L. V. Sequist et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

(2011) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

(2011) Zengliu Su et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

(2010) D Handolias et al.   BRITISH JOURNAL OF CANCER

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma

(2010) Carmit Levy et al.   MOLECULAR CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

(2010) E F Dunn et al.   ONCOGENE

Melanoma from bench to bedside: meeting report from the 6th international melanoma congress

(2010) D. E. Fisher et al.   Pigment Cell & Melanoma Research

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

(2009) J Bauer et al.   BRITISH JOURNAL OF CANCER

Response to Imatinib Mesylate Depends on the Presence of the V559A-Mutated KIT Oncogene

(2009) Patrick Terheyden et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

(2008) X. Jiang et al.   CLINICAL CANCER RESEARCH

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

(2008) Michael B. Atkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

(2008) Jose Lutzky et al.   Pigment Cell & Melanoma Research

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation

(2007) Carolyn McGuinness   Frontiers in Bioscience-Landmark